Date: 2013-05-23
Type of information: Grant
Company: Arsanis Biosciences (Austria)
Investors: Austrian Research Promotion Agency (Austria)
Amount: € 1.4 million
Funding type: grant
Planned used: This grant will support antibody discovery and development against nosocomial pathogens.
Others: * On May 23, 2013, Arsanis Biosciences announced the award of a major grant for the development of new therapeutics against severe pneumococcal infections. The grant is awarded by the FFG (Forschungs-Förderungs-Gesellschaft
or “FFG”), the leading public funding agency for translational research in Austria. The initial support from the FFG amounts to € 1.4 million; additional funding of up to a € 9 million is anticipated in the following three years.
This award marks the third consecutive year that Arsanis has secured significant non-dilutive funding from public agencies, having received grants from the FFG in 2011 and 2012 to support antibody discovery and development against nosocomial pathogens. Arsanis has to date received € 3,8 million from these grants, and expects to receive another € 10 million over the next four years.
Therapeutic area: Infectious diseases
